
    
      A Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups study in which subjects will
      be randomized to receive either BOL-DP-o-05 or placebo as an Add-On Treatment. The study
      evaluates the effect of BOL-DP-o-05 for Preservation of Beta-Cell Function in Subjects with
      Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM). The study includes a screening period up to
      three weeks followed by a 48-week treatment period
    
  